$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Aurora Kinase C - Pipeline Review, H2 2019
[Published by Global Markets Direct]

Published by Global Markets Direct: 27 Dec 2019 | 241515 | In Stock
Related Topics: Breast Cancer , Cancer , Leukemia , Lung Cancer , Lymphoma , Ovarian Cancer , Prostate Cancer , Protein

Introduction

Aurora Kinase C - Pipeline Review, H2 2019

Summary

According to the recently published report 'Aurora Kinase C - Pipeline Review, H2 2019'; Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Aurora Kinase C is a member of the Aurora subfamily of serine/threonine protein kinases. Aurora Kinase C is a chromosomal passenger protein that forms complexes with Aurora-B and inner centromere proteins and plays an important role in organizing microtubules in relation to centrosome function during mitosis. It is over expressed in several cancer cell lines and involved in oncogenic signal transduction.

The report 'Aurora Kinase C - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer and Triple-Negative Breast Cancer (TNBC).

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

- The report reviews Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Aurora Kinase C - Pipeline Review, H2 2019 [Published by Global Markets Direct]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Overview

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Companies Involved in Therapeutics Development

    AbbVie Inc

    Amgen Inc

    Cielo Therapeutics Inc

    Nemucore Medical Innovations Inc

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Drug Profiles

    AMG-900 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CCT-137690 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    danusertib - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ilorasertib - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NMI-900 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Dormant Products

    Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Discontinued Products

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

241515 | GMDHC2124TDB

Number of Pages

35

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Aurora Health Care, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAurora Health Care, Inc. (AHC) is a not-for-profit healthcare organization. The service portf...
29 Jul 2016 by Global Data USD $250 More Info
Aurora Spine Corporation (ASG) - Medical Equipment - Deals and Alliances Profile
SummaryAurora Spine Corporation (Aurora) is a medical equipment company that concentrates on introdu...
20 Jul 2016 by Global Data USD $250 More Info
Aurora Spine Corporation (ASG) - Financial and Strategic SWOT Analysis Review
SummaryAurora Spine Corporation (Aurora) is a medical equipment company that concentrates on introdu...
11 Jul 2016 by Global Data USD $300 More Info
Aurora Spine Corporation (ASG) - Product Pipeline Analysis, 2016 Update
SummaryAurora Spine Corporation (Aurora) is a medical equipment company that concentrates on introdu...
29 Jun 2016 by Global Data USD $750 More Info
Aurora Health Care, Inc. - Strategic SWOT Analysis Review
Aurora Health Care, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the ...
28 Jun 2016 by Global Data USD $125 More Info
Aurora Diagnostics, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAurora Diagnostics, LLC (Aurora Diagnostics) is a healthcare service provider that offers pat...
27 Apr 2016 by Global Data USD $250 More Info
Aurora Health Care, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAurora Health Care, Inc. (AHC) is a not-for-profit healthcare organization. It provides integ...
12 Apr 2016 by Global Data USD $250 More Info
Aurora Diagnostics, LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAurora Diagnostics, LLC (Aurora Diagnostics) is a healthcare service provider that offers pat...
09 Mar 2016 by Global Data USD $250 More Info
Aurora Health Care, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryAurora Health Care, Inc. (AHC) is a not-for-profit healthcare organization. It provides integ...
03 Mar 2016 by Global Data USD $250 More Info
Aurora Health Care, Inc. - Strategic SWOT Analysis Review
Aurora Health Care, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the ...
03 Nov 2015 by Global Data USD $125 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Aurora Kinase C - Pipeline Review, H2 2019 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...